Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GRM5 | P41594 | 2/20 | 0.67 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712060 | 1.00 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4711058 | 0.81 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4712490 | 0.81 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29510104 | 0.80 | GRM4 (1.00) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL179801 | 0.80 | GRM4 (1.00) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL350949 | 0.80 | GRM4 (1.00) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4712658 | 0.80 | RAB9A (0.76) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL20314428 | 0.80 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29691623 | 0.78 | CYP11B1 (0.86) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29691639 | 0.78 | CYP11B1 (0.86) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| CN-1262676-A | Pyridine derivatives | NOVARTIS AG (CH) | 2000-08-09 | — | — | CN | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1117403-B1 | MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PAIN AND ANXIETY | NOVARTIS AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |
| US-20010056084-A1 | MGluR5 antagonists for the treatment of pain and anxiety | ALLGEIER HANS (DE) | 2001-12-27 | — | — | US | disclosed |
| EP-1117403-A1 | MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PAIN AND ANXIETY | Novartis AG (CH) | 2001-07-25 | — | — | EP | disclosed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | disclosed |
| WO-2000020001-A1 | MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PAIN AND ANXIETY | NOVARTIS AG (CH) | 2000-04-13 | — | — | WO | disclosed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056084-A1 | MGluR5 antagonists for the treatment of pain and anxiety | GRM5, GRIK5, GRM1 | NPC1 3547/4885RAB9A 2149/4885MEN1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.